UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 128

Sortiert nach

Resistance to Second-Generation HIV-1 Maturation Inhibitors

Journal of virology, 2019-03, Vol.93 (6)

2019

Volltextzugriff (PDF)

A single G10T polymorphism in HIV-1 subtype C Gag-SP1 regulates sensitivity to maturation inhibitors

Retrovirology, 2021-04, Vol.18 (1), p.9-9, Article 9

2021

Volltextzugriff (PDF)

Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection

The Journal of experimental medicine, 2004-11, Vol.200 (10), p.1337-1346

2004

Volltextzugriff (PDF)

A Single Polymorphism in HIV-1 Subtype C SP1 Is Sufficient To Confer Natural Resistance to the Maturation Inhibitor Bevirimat

Antimicrobial Agents and Chemotherapy, 2011-07, Vol.55 (7), p.3324-3329

2011

Volltextzugriff (PDF)

In Vitro Resistance to the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PA-457 (Bevirimat)

Journal of Virology, 2006-11, Vol.80 (22), p.10957-10971

2006

Volltextzugriff (PDF)

Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice

PloS one, 2007-11, Vol.2 (11), p.e1251-e1251

2007

Volltextzugriff (PDF)

3-O-(3′,3′-Dimethysuccinyl) Betulinic Acid Inhibits Maturation of the Human Immunodeficiency Virus Type 1 Gag Precursor Assembled In Vitro

Journal of Virology, 2006-06, Vol.80 (12), p.5716-5722

2006

Volltextzugriff (PDF)

Direct Evidence that C-Peptide Inhibitors of Human Immunodeficiency Virus Type 1 Entry Bind to the gp41 N-Helical Domain in Receptor-Activated Viral Envelope

Journal of Virology, 2003-07, Vol.77 (13), p.7669-7672

2003

Volltextzugriff (PDF)

Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors

Antimicrobial agents and chemotherapy, 2016-01, Vol.60 (1), p.190-197

2016

Volltextzugriff (PDF)

Identification of potent maturation inhibitors against HIV-1 clade C

Scientific reports, 2016-06, Vol.6 (1), p.27403-27403, Article 27403

2016

Volltextzugriff (PDF)

Capture of an early fusion-active conformation of HIV-1 gp41

Nature structural biology, 1998-04, Vol.5 (4), p.276-279

1998

Volltextzugriff (PDF)

Elevated temperature triggers human respiratory syncytial virus F protein six-helix bundle formation

Virology (New York, N.Y.), 2010-01, Vol.396 (2), p.226-237

2010

Volltextzugriff (PDF)

Determinants of activity of the HIV-1 maturation inhibitor PA-457

Virology (New York, N.Y.), 2006-12, Vol.356 (1), p.217-224

2006

Volltextzugriff (PDF)

The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV

Expert opinion on investigational drugs, 2005-06, Vol.14 (6), p.681-693

2005

Volltextzugriff (PDF)

Peptides Corresponding to the Heptad Repeat Motifs in the Transmembrane Protein (gp41) of Human Immunodeficiency Virus Type 1 Elicit Antibodies to Receptor-Activated Conformations of the Envelope Glycoprotein

Journal of Virology, 2001-09, Vol.75 (18), p.8859-8863

2001

Volltextzugriff (PDF)

3- O-Glutaryl-dihydrobetulin and related monoacyl derivatives as potent anti-HIV agents

Bioorganic & medicinal chemistry letters, 2004-12, Vol.14 (23), p.5851-5853

2004

Volltextzugriff (PDF)

Peptides Corresponding to a Predictive α-Helical Domain of Human Immunodeficiency Virus Type 1 gp41 are Potent Inhibitors of Virus Infection

Proceedings of the National Academy of Sciences - PNAS, 1994-10, Vol.91 (21), p.9770-9774

1994

Volltextzugriff (PDF)

Peptides corresponding to a predictive (alpha)-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

Proceedings of the National Academy of Sciences - PNAS, 1994-10, Vol.91 (21), p.9770

1994

Volltextzugriff (PDF)

3-O-Glutaryl-dihydrobetulin and Related Monoacyl Derivatives as Potent anti-HIV Agents

ChemInform, 2005-03, Vol.36 (13), p.no-no

2005

Volltextzugriff (PDF)

Sind Kräftigungsübungen auf einer Beinpresse mit dem Behandlungsregime einer Teilbelastung vereinbar?

Sportorthopädie-Sporttraumatologie, 2016-06, Vol.32 (2), p.193-194

2016

Volltextzugriff (PDF)

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report

Journal of clinical lipidology, 2015-03, Vol.9 (2), p.129-169

2015

Volltextzugriff (PDF)

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary

Journal of clinical lipidology, 2014-09, Vol.8 (5), p.473-488

2014

Volltextzugriff (PDF)

Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA

Molecular therapy. Nucleic acids, 2012, Vol.1 (8), p.e37-e37, Article e37

2012

Volltextzugriff (PDF)

Spectrum of Disease in Hospitalized Newborns with Congenital Micrognathia: A Cohort of 3,236 Infants at North American Tertiary-Care Intensive Care Units

The Journal of pediatrics, 2024-02, Vol.265, p.113799-113799, Article 113799

2024

Volltextzugriff (PDF)

1 – 25 von 128

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(99)
Mit Volltextzugriff
(117)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Resistance to Second-Generation HIV-1 Maturation Inhibitors

A single G10T polymorphism in HIV-1 subtype C Gag-SP1 regulates sensitivity to maturation inhibitors

Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection

A Single Polymorphism in HIV-1 Subtype C SP1 Is Sufficient To Confer Natural Resistance to the Maturation Inhibitor Bevirimat

In Vitro Resistance to the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PA-457 (Bevirimat)

Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice

3-O-(3′,3′-Dimethysuccinyl) Betulinic Acid Inhibits Maturation of the Human Immunodeficiency Virus Type 1 Gag Precursor Assembled In Vitro

Direct Evidence that C-Peptide Inhibitors of Human Immunodeficiency Virus Type 1 Entry Bind to the gp41 N-Helical Domain in Receptor-Activated Viral Envelope

Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors

Identification of potent maturation inhibitors against HIV-1 clade C

Capture of an early fusion-active conformation of HIV-1 gp41

Elevated temperature triggers human respiratory syncytial virus F protein six-helix bundle formation

Determinants of activity of the HIV-1 maturation inhibitor PA-457

The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV

Peptides Corresponding to the Heptad Repeat Motifs in the Transmembrane Protein (gp41) of Human Immunodeficiency Virus Type 1 Elicit Antibodies to Receptor-Activated Conformations of the Envelope Glycoprotein

3- O-Glutaryl-dihydrobetulin and related monoacyl derivatives as potent anti-HIV agents

Peptides Corresponding to a Predictive α-Helical Domain of Human Immunodeficiency Virus Type 1 gp41 are Potent Inhibitors of Virus Infection

Peptides corresponding to a predictive (alpha)-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

3-O-Glutaryl-dihydrobetulin and Related Monoacyl Derivatives as Potent anti-HIV Agents

Sind Kräftigungsübungen auf einer Beinpresse mit dem Behandlungsregime einer Teilbelastung vereinbar?

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2

Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA

Spectrum of Disease in Hospitalized Newborns with Congenital Micrognathia: A Cohort of 3,236 Infants at North American Tertiary-Care Intensive Care Units

Suchergebnisse filtern